Cardiac amyloidosis (CA) comprises a heterogeneous group of medical conditions affecting the myocardium. It presents with 2
Introduction
Amyloidosis is a medical condition characterized by the buildup of proteinaceous byproducts, traditionally within the extracellular space, yielding histological alterations and organ disfunction [1] on its anatomical distribution. At present, nearly forty different human proteins can lead to relevant forms of amyloidosis, eight of which are capable of affecting the heart with variable incidences and severity [2, 3] . In addition to these forms, the detection of intracellular aggregates [4] of myocardial involvement by additional peptides of cardiac and extracardiac origins, complicates the overall portrait of [5] . Independently of the biological precursor and origin, all types of amyloidosis stem from a common pathogenic mechanism: an erroneous protein folding process, namely, "misfolding" [6] . A neosynthesized aminoacidic sequence is obligated to undergo the folding process in order to acquire its correct spatial conformation, which will dictate its physiological role, localization, interaction, and turnover [7] . A series of adverse events (genetic mutations, increased synthesis, iatrogenic facprotein per se) can alter this process in up to one-third of all synthesized proteins [8, 9] . Once an erroneously arranged protein (namely, a monomer) is generated and has overwhelmed protein quality control systems [10] , it starts aggregating into larger and more complex structures, such as pre-amyloid oligomers (PAO hereafter). Such a peculiar, abnormal and cytotoxic structure self-sustains its own accumulation and can travel and deposit in distant and vulnerable districts in a metastatic-like manner [11, 12] . Over time, PAO grow in size and yield more stable structures, such as linear and circular protofibrils and ultimately, amyloid mostly composed of protein bundles arranged in an ordered array from 7.5 to 10 nm in diameter of rigid, linear and non- [13, 14] . Such unique physico-chemical features determine distinctive tinctorial properties, allowing investiga--esis. While endomyocardial specimen positivity remains the current diagnostic gold standard, a less invasive diagnostic has reached comparable results only in cases of massive amyloid infiltration [15] . Similarly, smaller and/or intracellular deposits [4] might be detected only with expensive and nonroutine methods, such as electron microscopy.
Despite our better understanding of these mechanisms, which has been refined over the last few decades, unfortunately, amyloidosis is clinically suggestive only in a late stage of its natural history, and it might be undiagnosed in cases moniker of "the great pretender" [16] . On the other hand, nontraditional amyloidosis has been clinically undetected for long time.
Extensive descriptions of major cardiac amyloidosis (CA) subtypes are reported elsewhere [17] . In this review, we are offer a glimpse into the current state of knowledge of this disease to better understand its associated biomarkers.
Major known subtypes of cardiac amyloidosis
For a more extensive description of a greater number of kinds of CA, we suggest the cited review [18] .
Light chain amyloidosis (AL)
All subjects with AL suffer from a form of cell dyscrasia. Cardiac involvement prevalence is approximately 50% depending on the kind of hematologic disorder (eg, lymphomas, MGUS, the seventh decade of life, and men are frequently more -gesting a higher propensity of the former isotype to misfold [19] . Among systemic manifestations, periorbital and peribuccal purpura, together with macroglossia, are highly indicative of AL; moreover, heart failure represents the worst prognostic factor.
Systemic senile amyloidosis (SSA) with wild-type transthyretin (wtTTR)
in the absence of a mutation. A recent prospective cohort study extensively described the demographic, laboratory and cardiac morphofunctional features of this population [20] type of CA is of critical importance since the median survival from presentation is 4.6 years, and the median age at death is -munity as a threat to the elderly population.
Systemic familial amyloidosis (SFA) with mutated transthyretin (mutTTR) date [21] vary across mutations. In fact, neurological and cardiovascular involvement can be either present jointly or separately with different degrees of severity presenting at different age ranges [22, 23] . Etiological treatment is liver transplant, and overall survival at 4-year follow-up from presentation ranges from 79% to 16% for V30M and V122I mutations, respectively.
Amyloid A amyloidosis (AA)
diseases, persistent sepsis, or periodic fever syndromes, and its biological precursor is an acute phase reactant predominantly synthesized by the liver called serum amyloid A (SAA) [24] kidneys are frequently affected, possibly explaining the arterial hypertension commonly observed in this class of patients. CA is a rare finding, and its prevalence has been reported within 1%-15% of patients in two different studies [25, 26] median survival from diagnosis is 11 years.
Isolated atrial amyloidosis (IAA)
Among proteins, atrial natriuretic peptide (ANP) is also prone to misfold. In fact, it can lead to a peculiar form of CA constitutes the anatomical substrate for electrical disturbance [27] .
2 2 M) An iatrogenic form of CA can be observed in patients undera decade of dialytic treatment due to the concentration of 2 -microglobulin, a type 1 major histocompatibility complex (MHC I) subunit [28] . A long-standing hemoconcentration and homology with light chains immunoglobulins [29] represent two concomitant causes of amyloid formation in these patients [30] .
Newly recognized cardiac amyloidoses forms of CA with non-mutually exclusive features, such as atypical histological presentation (intracellular aggregates) associated with additional cardiac dysfunction, originating either by cardiac or extracardiac biological precursors. Both desmin [31, 32] [33] , which belong to the cardiomyocyte cytoskeleton apparatus, were found in intracellular aggregates in the context of dilated cardiomyopathy. In addition, novel piece to the complex biological jigsaw of Alzheimer's disease, supporting the hypothesis of Alzheimer's disease as a systemic or metastatic disease [34] .
Methods
We searched the PubMed library (last accessed on October 1, 2017) for articles in English with full text available and referwere "cardiac amyloidosis biomarkers" and "heart amyloid biomarkers", either alone or together in different combinations.
Biomarkers
In light of these remarkable differences among subtypes of amyloidosis, it is intuitive that a single biomarker cannot carry universal predictive power. Nevertheless, over the past years, a significant body of literature has been produced with the intention of exploring and testing a series of biomarkers for early disease detection, risk stratification, patient prognosis, and therapy monitoring. As correctly set out by Morrow and criteria: accuracy, informativeness, and superiority over other available tests [35] . Given the evolutionary nature of amyloidosis, biomarkers ---els of prevention (from primary to tertiary). In fact, they can be respectively employed for assessing risk stratification for future amyloid occurrence, early disease detection and prognosis evaluation in cases of cardiac involvement, as shown -loidogenic processes; however, it might help clinicians manage subjects at risk and affected patients over time. Despite of a lack of biomarkers for the newly discovered subtypes and biomarkers could be included and classified on the basis of their prediction to pinpoint the exact biochemical abnormalcurrently available knowledge on biomarkers tested in amyloidosis by CA subtype.
Biomarker classes
Due to the amount of literature available and to facilitate a rapid understanding, we start by evaluating and discussing late-stage biomarkers and proceed backwards to early-stage at present. Late-stage biomarkers for cardiac amyloidosis Amyloidosis is frequently diagnosed at a late timepoint when the myocardium is already infiltrated by amyloid fibers. At this stage, traditional cardiac involvement is easily detectable with different methods: imaging, histological and clinical assessment. In this phase, cardiac impairment is characterized by preserved/suboptimal systolic function and reduced degree heart failure with preserved ejection fraction (HFpEF) [36] . For this reason, the vast majority of biomarkers in CA are the ones also employed in case of heart failure of different etiologies.
biomarkers has also contributed to the delayed recognition of other forms of cardiomyopathy with newly recognized amybroader application across all subtypes (AL, SFA, SSA, AA, etc ones, provide information related to established molecular and cellular dysfunctions occurring in heart failure: myocyte apoptosis (cardiac troponins), increased fibrotic deposition, sustained inflammation and abnormal myocardial stretch- [37, 38] in the bloodstream [39] [40] [41] [42] . At present, these cardiac biomarkers are globally accepted as prognostic tools for hard clinical endpoints in different subclasses of amyloidosis (AL, SFA, and SSA). Markers of [43] , together with even their combined association), have shown high predictive power [44] . In recent years, high sensitivity cardiac troponin it has set a novel gold-standard, particularly in AL. In fact, mortality rates [45] and strongly correlate with NYHA functional class, LVEF, and left ventricular wall thickness [46] . As are applied in CA prognosis [47] cerned, a recent study has proposed different cut-off values by 2480 pg/mL and 3470 pg/mL, respectively [48] . According to Ishiguro and colleagues, a cut-off value of 200 pg/mL for BNP -tion [49] . In the setting of CA with cardiac onset, this class of markers might provide information regarding cardiac involvement and the degree of dysfunction both at single cell and organ levels.
Mid-stage biomarkers for cardiac amyloidosis
Cell vulnerability and death in CA can be linked to sustained -mulation or more likely, the presence of PAOs, which are now believed to be the most prominent driving force in protein misfolding related diseases [50] . Effectors or sensors of damage, -most frequent subpopulation analyzed for this matter.
decoy receptor, has been proven to be an independent powerful marker of prognosis in AL [51] . By binding to IL-33, it lowhypertrophy of its ligand [52] . A cut-off value of 30 ng/mL has were 81% and 52%, respectively.
ADM gene encodes a pre-pro-hormone that is subsequently cleaved, generating three distinct vasoactive peptides: adrenomedullin, adrenotensin and proadrenomedullin. Along with these peptides, a fourth seemingly inac- [53] . Despite its apparent inertness, it is ubiquitously expressed at high levels in various districts, such as bone, adrenal cortex, kidney, blood vessels, heart, adipose tissue and anterior pituitary, and it is likely related to vascular permeability and inflammation, thereby representing a predictor of early outcomes in acute settings [54, 55] . Values above 0.75 nmol/L predicted an increased has a role in adverse systemic responses in AL [56] . As anticipated, in addition to cardiomyocyte death, endothelial loss should be investigated. von Willebrand Factor (vWF) was evaluated as an additional marker of vascular damage. Values above 230 UI/dL were associated with poor prognosis independently of the clinical stage of AL patients [57] . Interestingly, hepatocyte growth factor (HGF) was significantly higher in AL than in other cardiac maladies (HF, LVH, or SSA without cardiac involvement) and was slightly increased in SSA with cardiac infiltration. A cut-off value of 622 pg/mL for HGF generated two cohorts with the most divergent results in terms of survival estimates at 5-year follow-up, which were 70% vs 30% for values below and above the median, respectively [58] must be elucidated: the authors have hypothesized a putative angiogenic role of HGF in response to amyloid deposition in vessels. Nevertheless, endothelial mesenchymal transition of action, ultimately leading to cardiac dysfunction as high HGF concentrations shift the myocardium towards fibrotic changes [59] . Despite being a simple speculation, this intriguing hypothesis should be carefully tested in the setting of human CA in the future [60] . Finally, extracellular matrix (ECM) remodeling has been evaluated in the plethora of pathological events occurring with CA, sustaining abnormal collagenolytic activity in the human myocardium. A coupled increase of serum matrix metalloproteinases-9 (MMP-9) together with tissue inhibitor metalloof light chains in cardiac ECM compared to transthyretin or is associated with an accelerated amyloidogenic process like what occurs in AL [61] . As far as this class is concerned, this group of biomarkers can detect initial molecular abnormalities and describe a biological footprint occurring in amyloidogenic -tion can discriminate between the different etiologies of HF and therefore stratify patients based on the effective mechanism of damage.
Early stage biomarkers for cardiac amyloidosis -els outside the physiological kappa/lambda ratio range (0.26 to 1.65) are suggestive of abnormal clonal expansion (<0.26 [62] . In addition, FLC values are quantitatively evaluated as they carry a prognostic value either alone or in association with other parameters.
involvement of a higher number of organs, constituting a reli- able predictor of mortality in an observed cohort of AL [63] and in patients undergoing stem cell transplantation [64] . With the same intention, a composite model was conceived by employ--ciation with FLC and by assigning a score of 1 for each marker with a level above the cut-off value. In this manner, four different stages (I to IV) were generated; the survival rates at 5-year follow-up for stages I, II, III, and IV were 68%, 60%, 27% and 14%, respectively [65] . Concerning AL, bone remodeling represents a local critical event in the natural history of cell dyscrasias, and osteopontin (OPN) and osteoprotegerin (OPG) have found applications in and osteoclasts, although OPN modulations are observed in various cardiac pathological conditions, particularly in myocytes [66] member, and it acts as a decoy receptor for the receptor actiinhibitor of osteoclastogenesis. Nevertheless, its expression is not limited to the bone marrow as endothelial and smooth muscle cells express abundant levels, suggesting pleiotropic [67] found that OPN is associated with worse NYHA functional class and morphofunctional parameters [68] cut-off value of 426.8 ng/mL for predicting overall mortality.
to distinguish AL compared to controls or hematological -cantly higher in cases of cardiac involvement and was directly features suggest the broader applicability of OPN and OPG beyond CA, such as in atherosclerosis and HF, and requires future studies for a deeper understanding of their effective role [69] . In AA, the biological precursor of PAOs, namely, SAA, represents the most powerful predictor of overall mortality as its increase is highly correlated with relative death risk [25] . Of and predictor of mortality in coronary artery disease, it should not be considered to be a sole marker for CA [70] .
2 -microglobulin was found to be increased in a series of patients with amyloidosis presented by Gertz nearly of mortality in patients with or without HF; a value above 2.7 mg/L was an indicator of poor prognosis [71] . As for mutated transthyretin, a genetic test should be considered in the diagnostic algorithm even in the case of a negative family history of amyloidosis. Such a test provides additional information to proteomic assays and allows an early diagnosis for anticipated liver transplantation before the amyloid load overwhelms cardiac resistance and function [72] .
Directions for future biomarkers
With larger cohorts and higher numbers of parameters, future studies will likely revise the cut-off values over-time. Nevertheless, future investigations should aim at identifying novel biomarkers and creating an updated scoring system with higher predictive values than the present ones. Predicting patients' response to therapy or regimen efficacy represents an additional expanding field of interest in biomarker research. At present, this specific application is limited to few subclasses of CA because liver transplant and chemotherapy are the only etiological treatments against SFA and AL, respectively. As recently evaluated by Sperry and colleagues, a triple combined therapy (bortezomib, dexamethasone, and an alkylating agent) appears to be superior to other treatments with a survival rate of approximately 60% vs 30% at 2-year follow-up [73] . In this study, FLC was the only covariate capable of increasing the survival predictability of a model upon adjustment.
As Palladini correctly noted, multiple organ dysfunctions are observed in amyloidosis, and renal impairment is not an uncommon finding, especially in AL. For this reason, bioas renal dysfunction can alter their clearance, requiring corrected cut-off values [74] . Concerning scoring systems, the association of established phosphatase, C-terminal and N-terminal telopeptide, and tarwww.chinaphar.com Luciani M et al Acta Pharmacologica Sinica would be tailoring the detection of misfolding occurrence and PAO accumulation, which would lead to interesting results. thickness and therefore the natural history of CA, must be pursued as it will have two major consequences. First, detecting CA before ventricle thickening and excessive amyloid load disposal since HF remains as the worst prognostic factor [75, 76] . Second, a better comprehension of this disease will guide us towards effectively designing and introducing etiological therapies, tackling misfolding itself.
